Suicide Associated With Sanofi-Aventis’ Acomplia, U.K. Agency Says
This article was originally published in The Pink Sheet Daily
Executive Summary
One suicide and 48 suicidal ideation cases reported following treatment with Acomplia between June 2006 and May 9.
You may also be interested in...
FDA Drops “Suicidality” Term, Urges Broader Risk Assessment During Development
Revised draft guidance retains eight categories of drugs to be evaluated for suicidal ideation and behavior in clinical trials, but says assessments could be conducted more broadly and “encourages” sponsors to discuss the possibility with the review division.
Sanofi’s Rimonabant Off The European Market; CHMP Finds Risk Management Plan Does Not Adequately Address Depression
Acomplia use doubles risk of psychiatric disorders in overweight patients, European review finds.
Sanofi’s Rimonabant Off The European Market; CHMP Finds Risk Management Plan Does Not Adequately Address Depression
Acomplia use doubles risk of psychiatric disorders in overweight patients, European review finds.